Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome (HOT-LoCO)
Hyperbaric Oxygen for Treatment of Long COVID Syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial
Sponsor: EDC Scandinavia AB
A PHASE2 clinical study on COVID-19 and Post COVID Condition, this trial is completed. The trial is conducted by EDC Scandinavia AB and has accumulated 10 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Oct 2021 — Feb 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EDC Scandinavia AB
- Karolinska Institutet
- Karolinska Trial Alliance
- Karolinska University Hospital
- Region Stockholm
- Swedish Heart Lung Foundation
- The Swedish Research Council
For direct contact, visit the study record on ClinicalTrials.gov .